Seesaw tau lepton mass and calculable neutrino masses in a 3-3-1 model

In a version of the 3-3-1 model proposed by Duong and Ma the introduction of the scalar sextet for giving mass to the charged leptons is avoided by adding a singlet charged lepton. We show that in this case the $\tau$ lepton gains mass through a seesaw--like mechanism. Besides we show how to generate neutrino masses at the tree and at the 1-loop level with the respective Maki-Nakagawa-Sakata leptonic mixing matrices.Comment: revtex, 5 pages and one eps figure. Published versio

Constraints on exotic lepton doublets with minimal coupling to the standard model

We investigate the consequences of introducing a set of exotic doublet leptons which couple to the standard model leptons in a minimal way. Through these additional gauge invariant and renormalizable coupling terms, new sources of tree-level flavor changing currents are induced via mixing. In this work, we derive constraints on the parameters that govern the couplings to the exotic doublets by invoking the current low-energy experimental data on processes such as leptonic Z decays, $\ell \rightarrow 3 \ell'$, $\ell \rightarrow \ell' \gamma$, and $\mu$-$e$ conversion in atomic nuclei. Moreover, we have analyzed the role these doublets play on the lepton anomalous magnetic moments, and found that their contribution is negligible.Comment: 18 pages, 1 figure, 2 tables (REVTeX4.1); v2: added discussions in Sec.II, III & IX and new ref. To appear in JHEP. arXiv admin note: text overlap with arXiv:1011.473

The discovery and development of Eg5 inhibitors for the clinic

The mitotic kinesin Eg5 (also known as kinesin spindle protein, KSP, Kif11, a member of the kinesin-5 family) represents an attractive oncology drug target in the ongoing development of anti-mitotic drugs that selectively block mitosis through disruption to the mitotic spindle. In this state-of-the-art review, we outline the progress that has been made in the development of Eg5 inhibitors for clinical use. We evaluate the preclinical development and attributes of key Eg5 inhibitors that have undergone clinical evaluation or extensive preclinical optimisation, and discuss the medicinal chemistry strategies utilised in their design to overcome the challenges encountered during lead optimisation. We critically analyse the progress that has been made towards delivering clinical benefits, and the wider implications this has in the utility of mitotic kinesin inhibitors as prospective oncology drugs